FDA Approval Activities for this Drug
Panretin (alitretinoin) Gel, 0.1%, Ligand NDA 20-886 2/2/99 2/5/99 2/5/99 6/16/99
Panretin Indication: Treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.
For the latest approval information, locate this drug using this index.